MLCARE · Machine Learning Computational Advancements for peRsonalized mEdicine

Линиите свързват координатора с партньорите.

Накратко на български

Цел на проекта

Personalized medicine represents a paradigm shift in healthcare, transitioning from generalized treatment strategies to highly personalized care. This transformation is driven by rapid advancements in digital technologies, which generate massive volumes of data from diverse sources, including genomic sequences, high-resolution imaging, wearable devices, and electronic health records (EHRs). However, despite an annual estimate of 50 petabytes of data generated per hospital, only a fraction is utilized effectively. Harnessing this untapped potential offers a transformative opportunity to uncover novel disease mechanisms and deliver more precise and effective therapeutic interventions.The MLCARE project seeks to revolutionize personalized medicine by developing cutting-edge AI solutions that integrate genomic, clinical, and environmental data into holistic, multimodal patient representations. Through innovative approaches such as Foundation Models and advanced generative AI methods, MLCARE will address critical challenges in processing complex, high-dimensional, and multimodal datasets. Emphasis will be placed on ensuring the trustworthiness, explainability, and security of AI applications to support real-world clinical decision-making.A core mission of MLCARE is to train a new generation of interdisciplinary researchers with expertise spanning AI, computational biology, and healthcare. The program will equip doctoral candidates with the technical, analytical, and ethical skills needed to lead the future of patient-centered, AI-driven medicine. By combining state-of-the-art research with a comprehensive training program, MLCARE aims to set new standards in personalized healthcare, ensuring equitable, data-driven solutions that improve outcomes across diverse populations. This project is poised to position Europe at the forefront of global innovation in precision medicine, delivering a timely and impactful response to evolving healthcare challenges.

Оригинален текст от CORDIS (на английски).

Участници

• UNIVERSIDAD CARLOS III DE MADRID · Getafe (Madrid)КоординаторИспания
• ASTRAZENECA FARMACEUTICA SPAIN, S.A · MADRIDИспания
• ASTRAZENECA UK LIMITED · CAMBRIDGEОбединеното кралство
• EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH · ZuerichШвейцария
• EVIDENCE-BASED BEHAVIOR, SL · LeganesИспания
• FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER · BarcelonaИспания
• FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANON · MadridИспания
• FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P. · SevillaИспания
• HMNC HOLDING GMBH · MUNCHENГермания
• INSTITUT PASTEUR · ParisФранция
• KOBENHAVNS UNIVERSITET · KOBENHAVNДания
• LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN · PlaneggГермания
• MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV · MUNCHENГермания
• NOVO NORDISK A/S · BagsvaerdДания
• PHARMATICS LIMITED · EDINBURGHОбединеното кралство
• Pixelgen Technologies AB · StockholmШвеция
• SIEMENS HEALTHINEERS AG · FORCHHEIMГермания
• TARTU ULIKOOL · TartuЕстония
• THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD · OxfordОбединеното кралство
• UNIVERSIDAD DE SEVILLA · SevillaИспания
• UNIVERSIDAD POMPEU FABRA · BarcelonaИспания
• UNIVERSITE DE LIEGE · LIEGEБелгия
• UNIVERSITE PARIS CITE · ParisФранция
• UNIVERSITEIT MAASTRICHT · MaastrichtНидерландия

Връзки

• Виж в CORDIS
• DOI: 10.3030/101226456
• https://mlcare.webs.tsc.uc3m.es/